Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47581 | 0.86 | MAPK1 (0.45) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL128148 | 0.77 | MAPT (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL12238619 | 0.77 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL21841894 | 0.76 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL25900797 | 0.75 | LMNA (0.33) | MAPK1KMT2AYEATS4LMNATSHR | |
| SCHEMBL128147 | 0.75 | LMNA (0.33) | MAPK1KMT2AYEATS4LMNATSHR | |
| SCHEMBL1164060 | 0.75 | CES2 (0.38) | MAPK1KMT2AYEATS4LMNATSHR | |
| SCHEMBL25451234 | 0.74 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL21775973 | 0.74 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL14997805 | 0.74 | DAO (0.45) | MAPK1KMT2AYEATS4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-8309730-B2 | Nonsteroidal compounds useful as modulators of glucocorticoid receptor AP-1 and/or NF-kappab acitivity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110263494-A1 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1086/4885KMT2A 4333/4885YEATS4 1844/4885 |
| US-20110263494-A1 | NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF | NFKBIA, RELA, NR3C1 | MAPK1 689/4885KMT2A 4318/4885YEATS4 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.